Effects of precondition α2-adrenoceptor agents on memory- and anxiety-related processes in the transient cerebral ischemic rats

Nasehi, Mohammad; Imani, Esmail; Ebrahimi-Ghiri, Mohaddeseh; Sabouri-Khanghah, Vahid; Zarrindast, Mohammad‐Reza

doi:10.1007/s00210-019-01723-1

Cited by 1 publication

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The percentage of time spent in open arms (%OAT: (time in open arm/300)×100) and the number of entries to the open arms (OAE) were used as a measure for anxiety (Ebrahimi-Ghiri et al, 2019b). In addition, the number of total arm entries was used as a measure for locomotor activity (Ebrahimi-Ghiri et al, 2019b; Nasehi et al, 2020). The maze was cleaned with 75% ethanol between tests.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels

2020

Self Cite

View full text Add to dashboard Cite

Background: Methamphetamine is an addictive stimulant that possesses toxicity in the brain when taken repeatedly or at higher doses. Methamphetamine neurotoxicity is associated with numerous forms of mental impairment, including depression and anxiety. Evidence has also demonstrated that the endocannabinoid system is involved in the regulation of anxiety and depression. Aims: This study was designed to determine the involvement of the endocannabinoid system in anxiety- and depression-related behaviors in methamphetamine-withdrawal male NMRI mice. Methods: The elevated plus maze and forced swim test were used to assess the level of anxiety and depression. Results: We found that methamphetamine (30 mg/kg, intraperitoneal) evoked depressive- and anxiogenic-like effects at 3 days post-administration. Injection of URB597 (5–10 ng/mouse, intracerebroventricular), 10 min before the test, prevented the emotional deficits induced by methamphetamine withdrawal. Moreover, the cannabinoid receptor type 1 antagonist AM251 (1 μg/mouse) or cannabinoid receptor type 2 antagonist AM630 (5 and 10 μg/mouse) suppressed the antidepressant activity in the methamphetamine-withdrawal mice treated with URB597. The transient receptor potential vanilloid 1 antagonist capsazepine (25 μg/mouse) prevented while capsazepine (100 μg/mouse) potentiated the antidepressant efficacy in the methamphetamine-withdrawal mice treated with URB597. The higher dose of AM630 and two higher doses of capsazepine had antidepressant efficacy, by themselves. Furthermore, capsazepine (50 μg/mouse) increased locomotion in the methamphetamine-withdrawal mice treated with URB597. Conclusions: The results suggest that URB597 has a potential for preventing methamphetamine withdrawal-evoked anxiety and depression. Cannabinoid type 1 receptors, cannabinoid type 2 receptors and transient receptor potential vanilloid 1 differently affect depression-related behaviors in methamphetamine-withdrawal mice treated with URB597.

show abstract

Section: Methodsmentioning

confidence: 99%

“…(Ebrahimi-Ghiri et al, 2019b). In addition, the number of total arm entries was used as a measure for locomotor activity (Ebrahimi-Ghiri et al, 2019b;Nasehi et al, 2020). The maze was cleaned with 75% ethanol between tests.…”

Section: Elevated Plus Maze (Epm)mentioning

confidence: 99%